TrialHepatology communications2022

Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB-506 from Phase 1 studies in healthy subjects and those with hepatitis B.

Man-Fung Yuen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.